There's currently no cure for dementia. Although some recently developed drugs show promise in slowing the progress of the disease, these are both costly and may have limited benefit for many patients ...

The latest findings, published in the medical journal BMJ, show a "substantial" link between certain anticholinergic drugs ...

EXISTING drugs already dished out on the NHS could slash dementia risk, a new study has revealed. While new drugs are emerging to treat the memory-robbing disease, experts argue that repurposing ...

More must be done to see whether existing drugs could help to tackle dementia, scientists have said after finding that a number of common treatments may affect a person’s risk. While some new ...

A new study from the University of East Anglia has found that long-term use of certain antidepressants may increase the risk of dementia, even if taken up to 20 years before a diagnosis. The study ...

Analysis of millions of patient records suggests potential benefits from antimicrobials and harms from antipsychotics. Study: Data-driven discovery of associations between prescribed drugs and ...

Some antibiotics, antivirals, vaccinations and anti-inflammatory medications are linked to a reduced risk of dementia, a study shows. The report was published Tuesday in Alzheimer’s & Dementia.

Scientists hope to investigate whether common drugs could be used to help fight dementia after ibuprofen and some prescription antibiotics, antivirals and vaccines were associated with a reduced ...

Richard Oakley, Associate Director of Research and Innovation at Alzheimer's Society, commented on the future of dementia diagnosis. “The full results are out and the science behind them is solid – ...

Medicare helps pay for some services at every stage of dementia. The areas of coverage include tests to evaluate a person’s thinking skills, home healthcare, prescription drugs, and hospice.

(MENAFN- The Conversation) There's currently no cure for dementia. Although some recently developed drugs show promise in slowing the progress of the disease, these are both costly and may have ...

Rahul Sidhu does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond ...